Joseph M Chan
Overview
Explore the profile of Joseph M Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ireland A, Hawgood S, Xie D, Barbier M, Lucas-Randolph S, Tyson D, et al.
bioRxiv
. 2024 Nov;
PMID: 39605338
Neuroendocrine and tuft cells are rare, chemosensory epithelial lineages defined by expression of ASCL1 and POU2F3 transcription factors, respectively. Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like...
2.
Quintanal-Villalonga A, Kawasaki K, Redin E, Uddin F, Rakhade S, Durani V, et al.
Signal Transduct Target Ther
. 2024 Jul;
9(1):189.
PMID: 39054323
Neuroendocrine (NE) transformation is a mechanism of resistance to targeted therapy in lung and prostate adenocarcinomas leading to poor prognosis. Up to date, even if patients at high risk of...
3.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
4.
Finlay J, Ireland A, Hawgood S, Reyes T, Ko T, Olsen R, et al.
Cancer Cell
. 2024 May;
42(6):1086-1105.e13.
PMID: 38788720
The olfactory epithelium undergoes neuronal regeneration from basal stem cells and is susceptible to olfactory neuroblastoma (ONB), a rare tumor of unclear origins. Employing alterations in Rb1/Trp53/Myc (RPM), we establish...
5.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
6.
Taniguchi H, Chavan S, Chow A, Chan J, Mukae H, Rudin C, et al.
Front Immunol
. 2024 Mar;
15:1348982.
PMID: 38533509
Introduction: Immune checkpoint blockade (ICB) with or without chemotherapy has a very modest benefit in patients with small cell lung cancer (SCLC). SCLC tumors are characterized by high tumor mutation...
7.
Nabet B, Hamidi H, Lee M, Banchereau R, Morris S, Adler L, et al.
Cancer Cell
. 2024 Feb;
42(3):429-443.e4.
PMID: 38366589
Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer understanding of therapeutically relevant SCLC subsets could identify...
8.
Pai J, Hellmann M, Sauter J, Mattar M, Rizvi H, Woo H, et al.
Cancer Cell
. 2023 Mar;
41(4):776-790.e7.
PMID: 37001526
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq analysis of 187,650 T ...
9.
Seo Y, Zhang S, Jang J, Ko K, Kim K, Huang Y, et al.
bioRxiv
. 2023 Feb;
PMID: 36824957
Small cell lung cancer (SCLC) is aggressive with limited therapeutic options. Despite recent advances in targeted therapies and immunotherapies, therapy resistance is a recurring issue, which might be partly due...
10.
Chow A, Uddin F, Liu M, Dobrin A, Nabet B, Mangarin L, et al.
Immunity
. 2022 Dec;
56(1):93-106.e6.
PMID: 36574773
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8 T cells. Here, we comprehensively profiled CD39 expression in...